What is StrideBio?
StrideBio operates at the intersection of biotechnology and precision medicine, specializing in the development of next-generation gene therapies. Central to its market position is the STRIVE Capsid Platform, a proprietary technology designed to overcome traditional limitations in viral vector delivery. By integrating advanced AAV manufacturing services with a deep commitment to scientific integrity, the company is effectively bridging the gap between laboratory discovery and patient-centric clinical applications. StrideBio's focus on rare and life-threatening diseases positions it as a critical innovator in the biopharmaceutical ecosystem, providing scalable solutions that aim to improve long-term health outcomes.
How much funding has StrideBio raised?
StrideBio has raised a total of $97.2M across 2 funding rounds:
Series A
$15.7M
Series B
$81.5M
Series A (2018): $15.7M with participation from Takeda Ventures, UCB, Hatteras Venture Partners, and Alexandria Venture Investments
Series B (2021): $81.5M led by Octagon Capital, Novo Holdings, Sarepta Therapeutics, Pontifax, UF Innovate Ventures, Northpond Ventures, and Caas Capital Management
Key Investors in StrideBio
Sarepta Therapeutics
A global commercial-stage biopharmaceutical leader focused on precision genetic medicines for rare diseases, particularly neuromuscular disorders.
Pontifax
A venture capital firm specializing in groundbreaking life sciences innovations, providing strategic guidance to clinical-stage companies.
Hatteras Venture Partners
A long-standing venture firm dedicated to building transformative biotech and MedTech companies through strategic capital and operational support.
What's next for StrideBio?
With the successful closure of its latest financing, StrideBio is well-positioned to transition its lead candidates through critical clinical development phases. The strategic allocation of these funds will likely prioritize the expansion of its AAV manufacturing infrastructure and the acceleration of its internal pipeline. As the company matures, it will focus on strengthening its competitive moat through continued investment in its capsid engineering platform and potential strategic partnerships. The focus remains on achieving regulatory milestones and demonstrating the clinical efficacy of its therapeutic modalities, which will be essential for long-term value creation in the highly competitive gene therapy market.
See full StrideBio company page
